Bruce L. Levine, Ph.D.

Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. in Biology from the University of Pennsylvania and a Ph.D. in Immunology and Infectious Diseases from the Johns Hopkins University. The CVPF develops and tests novel cell and gene therapies in single center and multi-center clinical trials in patients with hematologic malignancies, solid tumors, HIV infection, and genetic disease. Twenty clean rooms and Quality Control laboratories staffed by 60 clinical laboratory scientists and regulatory professionals support the mission. Several CVPF trials have been first-in-human trials, including the first use of a lentiviral vector, the first infusions of zinc finger nuclease genome-modified cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 2700 cellular products administered to >1000 patients in clinical trials since 1996. Through these technologies, personalized and enhanced immunity has been engineered. T lymphocytes from HIV+ subjects have been rendered resistant to HIV infection and reinfused. T lymphocytes from cancer patients have been redirected with chimeric antigen receptors to hunt and destroy their malignancies, an investigational therapy that received the first Breakthrough Designation from the FDA for an academic institution and is currently in commercial development. Dr. Levine is co-inventor on 20 issued US patents and co-author of >120 publications. 


Gary C. du Moulin, Ph.D., M.P.H.

Adjunct Associate Professor of Regulatory Affairs.  Massachusetts College of Pharmacy and Health Sciences University. Previously, Dr. du Moulin served as Senior Director of Quality Aseptic Control for Genzyme (A Sanofi Company) where he participates in the development and execution of robust quality systems for Genzyme’s products. Dr. du Moulin joined Genzyme in 1995 after working for six years developing quality systems for cellular therapies for the treatment of renal cell carcinoma. Prior to his industrial experience, he spent 15 years on the faculty of Harvard Medical School in the Department of Anesthesia at Beth Israel Hospital. He has more than 150 publications in the areas of microbiology, epidemiology, and the regulation and quality control of living cells as a therapeutic modality. Dr. du Moulin received his B.S. in 1969 from Norwich University, an M.S. degree from Northeastern University, and M.P.H. and Ph.D. degrees from Boston University. He is retired from the U.S. Army Reserve at the rank of Colonel after 38 years of service.  Dr. du Moulin currently serves on U.S. Pharmacopoeia’s expert committee for Biological Analysis and formally on the Gene Therapy, Cell Therapy, and Tissue Engineering Expert Committee and chaired the ad hoc advisory panel for fetal bovine serum. He serves on the editorial board of Regenerative Medicine and is RAC certified and past Chairman of the Editorial Board of the Regulatory Affairs Professionals Society Magazine, RAPS Focus and was appointed to the Grants Review Working Group of the California Institute for Regenerative Medicine.


Philippe Moullier, M.D., Ph.D.

Founder and until Dec 2016, the Director of the research INSERM Unit UMR 1089 entitled « Translational Gene Therapy for Retinal and Neuromuscular Diseases » at the University of Nantes, France. He was also at the same time the Scientific Director of GENETHON, a nonprofit research institution, located near Paris, from Jan 2009 through Dec 2011. In 2014, he co founded HORAMA, a spin off dedicated to gene therapy for monogenic rare retinal diseases. He established a unique 16,150 ft2 BL2/BL3 confined large animal core facility located at the Nantes veterinary school. He was also key in the establishment of a full GMP-compliant manufacturing facility operated today by the Etablissement Français du Sang (EFS) located in Nantes. Since 2006 and until Jan 2016, Dr Moullier was an Adjunct Professor at the Molecular Genetics and Microbiology Department at the University of Florida, USA. Dr Moullier supervised more than 85 people scattered among the research groups in Nantes, the core facilities and administration, including junior faculty, post-docs, graduate students, undergraduate students, and technicians. His research efforts are focused on: (i) the basic virology of Adeno-Associated Virus with translational developments in recombinant virus assembly; (ii) the preclinical evaluation of recombinant viral vectors in large animal models of rare genetic disorders; (iii) the establishment of Phase I/II human clinical trials in retina and neuromuscular diseases; and (iv) basic viral vector biology (immunology and vector maintenance) in large animal models. Prior to joining the University of Nantes, Dr Moullier conducted research at the Pasteur Institute in Paris and at the Wistar Institute in Philadelphia where he was engaged in the development of MLV and adenovirus-derived recombinant viral vectors and their in vivo application. Dr Moullier was a postdoctoral fellow at Scripps Research Institute in La Jolla, received his PhD degree in Biochemistry from the University of Paris (Mentor Pr Donny Strosberg) and obtained a Master in Immunology at the Pasteur Institute. He also was an intern in nephrology and internal medicine, and received his MD degree from the University of Paris (mentor: Pr Claude Amiel). Dr Moullier has authored over 120 original publications describing virus biology, viral vector development, gene transfer and genetic diseases. He served as an expert to the EMA and at the ANSM Gene Therapy Advisory Board.  


Gabor Veres Ph.D.

Vice President Preclinical Research, bluebirdbio Inc.  Dr Veres joined the bluebird bio team in July 2010 as Vice President of Pre-clinical Research and Development. He has 20 years of experience in the development of cell and gene therapy products for the treatment of Severe Genetic Disorders, HIV and cancer. He initiated and coordinated multiple research programs including: viral gene delivery to correct genetic and acquired diseases, cancer vaccines, oncolytic viruses, Led several projects from pre-clinical research to clinical development. Prior to joining bluebird bio, he served as VP of Research and Development at Applied Genetic Technologies Corporation, a gene therapy company focusing on ophthalmology and for the treatment for Alpha One Antitrypsin Deficiency. Dr. Veres has managed biotechnology companies from discovery through late stage development, including cell and gene therapy platform technology. He worked at Sangamo as a Senior Director, at Genthon in France as Director of Research, Senior Director at CellGenesys Inc. and Director of Research at Novartis/Systemix.


Frank R. Witney, Ph.D.

Most recently served as President and Chief Executive Officer of Affymetrix, Inc. (now part of Thermo Fisher Scientific), which specialized in microarray technology and cellular analysis. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market leading ion and high performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix when it acquired Panomics Inc., a quantitative biology company, which he led as President and Chief Executive Officer. He previously held the role of President of PerkinElmer’s Drug Discovery Tools division following the acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market.  Dr. Witney was a post-doctoral fellow at the National Institutes of Health from 1980 to 1983 and holds a doctorate in molecular and cell biology from Indiana University. He earned an undergraduate degree in microbiology from the University of Illinois. Dr. Witney is currently Chairman of the Board for Gyros Protein Technologies AB and also holds Board positions for Cerus Corporation and Exagen Diagnostics.